In terms of ADMET analysis, Budmunchiamine L5 has good absorption, BBB penetration, and less toxicity in the human liver and may therefore be regarded as a safe lead drug for designing a novel ApoE4 inhibitor for AD therapy. The gene discussed is APOE; the disease is Alzheimer disease.